Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial ...

Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences' Sapien 3 Ultra system. The artificial heart valve is pushed through the blood vessels via a catheter and ...

SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...

Reaffirming original 2024 total company constant currency sales growth guidance of 8% to 10% Advancing broad portfolio of structural heart therapies with meaningful catalysts in 2025: TAVR growth ...

At 6 years, transcatheter aortic valve replacement (TAVR) appears to rival surgery for major adverse events in low-risk patients with severe aortic stenosis, but it may come at the cost of more ...

Please provide your email address to receive an email when new articles are posted on . Researchers analyzed outcomes among only women who underwent TAVR or surgery. TAVR was superior to surgery for ...

Over the last two decades, Edwards Lifesciences has demonstrated that it knows how to maintain leadership through innovation of tissue heart valves. Edwards remains the dominant force in surgical ...

Edwards Lifesciences EW has delivered an impressive return over the past year, with shares rallying 22.1%. The stock comfortably outpaced the industry’s 3.8% fall and closely tracked the S&P 500 ...

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...

NEW YORK--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (EW) will discuss the company’s focused strategy for long-term sustainable growth, provide an update on its technology pipeline to serve ...